Mylan Clears Runway For US Herceptin Biosimilar Launch
Executive Summary
The generic drug manufacturer is poised to be first to market with a biosimilar version of Roche’s blockbuster breast cancer therapy after reaching a license agreement. The date of a potential launch remains confidential.
You may also be interested in...
Big Brands Poised To Lose US Marketing Exclusivity In 2019
With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.
Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.